Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Pharmaceutical Investing Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
Brunswick Exploration Drills 36 Meters at 1.51% and Continues to Extend the Mineralized Footprint of Mirage
